ACC 2023: Late-Breaking Science Video Collection

Published: 06 March 2023

  • Views:

    Views Icon 5650
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Our regular review series View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provides a critical analysis of the late-breaking and featured science results and spotlights impactful data. 

 

For a deeper look into the key clinical trial data revealed at ACC 23, Dr Harriette Van Spall (McMaster University, Hamilton, CA) interviews the principal investigators in her regular Late-Breaker Discussion Series

 

For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research. 

More from this programme

Part 3

View from the Thoraxcenter

In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at ACC 2023. 

About the episode

We are joined by Dr Christie Ballantyne (Baylor College of Medicine, US) to discuss the results of a phase 2b clinical trial on the efficacy and safety of MK-0616, an oral macrocyclic PCSK9 inhibitor.

In this trial sponsored by Merck Sharp & Dohme LLC, MK-0616 was compared to a placebo in over 380 participants with hypercholesterolemia, whose low-density lipoprotein cholesterol (LDL-C) was measured over 8 weeks.

Results suggest that MK-0616 is safe and effective, with significant LDL cholesterol reduction.

Questions: 

  1. What is the importance of this trial?
  2. Please outline the patient population and study design.
  3. What are the key findings?
  4. What are the clinical implications of these findings?
  5. What are the next steps for MK-0616?

Recorded on site at ACC 2023, New Orleans.

Faculty Biographies

Christie Ballantyne

Christie Ballantyne

Chief of Cardiovascular Research and Director of the Center for Cardiometabolic Disease Prevention

Dr Christie Ballantyne is the Chief of Cardiovascular Research, Director of the Center for Cardiometabolic Disease Prevention, and Professor of Medicine at Baylor College of Medicine in Texas, US.

He received his MD from Baylor College of Medicine and performed both his internal medicine residency at The University of Texas Southwestern Medical School. He completed a cardiology fellowship at Baylor College of Medicine and an American Heart Association/Bugher Foundation Fellowship at the Howard Hughes Medical Institute and Institute for Molecular Genetics at Baylor.

Dr Ballantyne is an internationally-renowned expert on lipids, atherosclerosis and heart disease prevention. His research interest in the prevention of heart disease has led him to become an established investigator for the American Heart Association and to receive continuous funding from the NIH since joining the faculty in 1988 in basic research of leukocyte- endothelial interactions,…

View full profile

Comments

You must be to comment. If you are not registered, you can register here.